BRPI0807487A2 - Uso de antagonistas de il-23 para o tratamento de infecção - Google Patents

Uso de antagonistas de il-23 para o tratamento de infecção

Info

Publication number
BRPI0807487A2
BRPI0807487A2 BRPI0807487-9A BRPI0807487A BRPI0807487A2 BR PI0807487 A2 BRPI0807487 A2 BR PI0807487A2 BR PI0807487 A BRPI0807487 A BR PI0807487A BR PI0807487 A2 BRPI0807487 A2 BR PI0807487A2
Authority
BR
Brazil
Prior art keywords
antagonists
treat infection
infection
treat
Prior art date
Application number
BRPI0807487-9A
Other languages
English (en)
Inventor
Manfred Kopf
Lugina Romani
Robert A Kastelein
Alissa A Chackerian
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BRPI0807487A2 publication Critical patent/BRPI0807487A2/pt
Publication of BRPI0807487A8 publication Critical patent/BRPI0807487A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BRPI0807487A 2007-02-12 2008-02-08 Uso de antagonistas de il-23 para o tratamento de infecção BRPI0807487A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88947507P 2007-02-12 2007-02-12
PCT/US2008/001717 WO2008153610A2 (en) 2007-02-12 2008-02-08 Use of il-23 antagonists for treatment of infection

Publications (2)

Publication Number Publication Date
BRPI0807487A2 true BRPI0807487A2 (pt) 2015-09-01
BRPI0807487A8 BRPI0807487A8 (pt) 2016-02-10

Family

ID=40130357

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807487A BRPI0807487A8 (pt) 2007-02-12 2008-02-08 Uso de antagonistas de il-23 para o tratamento de infecção

Country Status (13)

Country Link
US (2) US8586035B2 (pt)
EP (1) EP2064246B1 (pt)
JP (2) JP5320301B2 (pt)
CN (1) CN101668775B (pt)
AU (1) AU2008262544B2 (pt)
BR (1) BRPI0807487A8 (pt)
CA (1) CA2677835A1 (pt)
CL (1) CL2008000418A1 (pt)
MX (1) MX2009008617A (pt)
NZ (2) NZ599827A (pt)
TW (1) TWI426918B (pt)
WO (1) WO2008153610A2 (pt)
ZA (1) ZA200906126B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
US8513208B2 (en) * 2008-02-28 2013-08-20 Argos Therapeutics, Inc. Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
WO2010027767A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Engineered anti-il-23r antibodies
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CN103282382B (zh) 2010-11-04 2017-11-03 勃林格殷格翰国际有限公司 抗il‑23抗体
WO2012093127A2 (en) * 2011-01-04 2012-07-12 Universität Zürich Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CH707029B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
KR102124758B1 (ko) 2012-05-03 2020-06-19 베링거 인겔하임 인터내셔날 게엠베하 항-ｉｌ-23ｐ19 항체
EP2866833B1 (en) 2012-06-27 2019-05-15 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US10406218B2 (en) * 2014-04-09 2019-09-10 La Jolla Institute For Allergy And Immunology Specific and unique T cell responses and molecular signatures for the treatment and diagnosis of Mycobacterium tuberculosis
JP2017524359A (ja) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
EA202193002A2 (ru) 2014-09-03 2022-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23a и фно-альфа, и его применение
CN105420238A (zh) * 2015-09-08 2016-03-23 中国农业科学院兰州兽医研究所 靶向抑制小鼠白细胞介素17A基因的序列siRNA-136
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2018067520A2 (en) * 2016-10-04 2018-04-12 Pop Test Oncology Llc Therapeutic agents and methods:
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US20200197389A1 (en) * 2017-05-12 2020-06-25 The Regents Of The University Of California Methods for detecting dysbiosis and treating subjects with dysbiosis
CN108743603B (zh) * 2018-06-22 2020-06-30 山东省千佛山医院 利巴韦林单用或联合氟康唑的抗真菌产品及其应用
CN112969473A (zh) * 2018-11-09 2021-06-15 学校法人立命馆 皮脂腺调节剂
CN112500490B (zh) * 2020-10-14 2022-05-03 华南农业大学 一种抗左旋氧氟沙星抗体的F(ab)2片段及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) * 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
US4218458A (en) * 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
EP0069442B1 (en) * 1981-06-06 1985-02-20 Pfizer Limited Antifungal agents, processes for their preparation, and pharmaceutical compositions containing them
EA002469B1 (ru) 1996-09-12 2002-06-27 Мерк Энд Ко., Инк. Способ лечения грибковой инфекции
CO4810232A1 (es) 1997-07-25 1999-06-30 Schering Corp Citoquinas de mamiferos y sus secuencias codificadoras
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP1181366B2 (en) 1999-06-01 2013-08-21 Merck Sharp & Dohme Corp. Mammalian receptor proteins; related reagents and methods
ATE389019T1 (de) 1999-09-09 2008-03-15 Schering Corp Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
JP5073909B2 (ja) 2000-05-10 2012-11-14 メルク・シャープ・アンド・ドーム・コーポレーション 哺乳動物レセプタータンパク質；関連する試薬および方法
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
EP1418936A2 (en) * 2001-05-09 2004-05-19 Alk-Abell A/S Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.
NZ539271A (en) 2002-10-30 2008-12-24 Genentech Inc Inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23)
CN1759123B (zh) * 2003-03-10 2011-04-13 先灵公司 Il-23激动剂及拮抗剂的用途；相关试剂
WO2004091519A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Methods of preventing or treating respiratory conditions
JP2007515939A (ja) * 2003-05-09 2007-06-21 セントカー・インコーポレーテツド ＩＬ−２３ｐ４０特異的免疫グロブリン由来タンパク質、組成物、方法および用途
ES2751414T5 (es) * 2003-07-08 2024-04-23 Novartis Pharma Ag Anticuerpos antagonistas a polipéptidos heterólogos IL-17 A/F
GB0329146D0 (en) 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
ATE533502T1 (de) * 2004-02-17 2011-12-15 Schering Corp Verfahren zur modulation der il-23-aktivität; relevante reagenzien
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
GB0507561D0 (en) 2005-04-14 2005-05-18 Trinity College Dublin Modulation of an immune response by filamentous haemagglutinin
EP1896073B1 (en) * 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
MX2008002179A (es) * 2005-08-25 2008-04-22 Lilly Co Eli Anticuerpos anti-il-23.
ES2619845T3 (es) 2005-08-31 2017-06-27 Merck Sharp & Dohme Corp. Anticuerpos anti-IL-23 diseñados por ingeniería genética
ES2517420T3 (es) 2005-12-29 2014-11-03 Janssen Biotech, Inc. Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
MX2009001620A (es) * 2006-08-11 2009-02-23 Schering Corp Anticuerpos para il-17a.
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
HUE042172T2 (hu) 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
CN103396489A (zh) 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
CN101675076B (zh) 2007-02-28 2013-09-18 默沙东公司 工程化的抗il-23r抗体
WO2010027767A1 (en) 2008-08-27 2010-03-11 Schering Corporation Engineered anti-il-23r antibodies

Also Published As

Publication number Publication date
CN101668775A (zh) 2010-03-10
ZA200906126B (en) 2010-06-30
TW200902062A (en) 2009-01-16
AU2008262544B2 (en) 2014-01-16
JP5320301B2 (ja) 2013-10-23
CA2677835A1 (en) 2008-12-18
JP2013014624A (ja) 2013-01-24
MX2009008617A (es) 2009-10-14
JP2010518087A (ja) 2010-05-27
CL2008000418A1 (es) 2008-11-14
NZ578955A (en) 2012-06-29
US8586035B2 (en) 2013-11-19
EP2064246B1 (en) 2013-05-22
US20140147442A1 (en) 2014-05-29
CN101668775B (zh) 2014-05-07
BRPI0807487A8 (pt) 2016-02-10
AU2008262544A1 (en) 2008-12-18
NZ599827A (en) 2013-11-29
WO2008153610A3 (en) 2009-03-19
WO2008153610A2 (en) 2008-12-18
US20100291084A1 (en) 2010-11-18
EP2064246A2 (en) 2009-06-03
TWI426918B (zh) 2014-02-21

Similar Documents

Publication Publication Date Title
BRPI0807487A2 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
SMT201500206B (it) Composti spiro-ossindolici e loro uso come agenti terapeutici
BR112012002331A2 (pt) composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
BRPI0921433A2 (pt) uso de anticorpos anti-cs1 para o tratamento de linfomas raros
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
SMT201400008B (it) Uso di betanecolo per il trattamento di xerostomia
BRPI0913086A2 (pt) Composições antimicrobianas e métodos de uso
BRPI0908428A2 (pt) uso de ranozalina para tratar a dor.
CL2007002837A1 (es) Uso de fenitoina para tratar mucositis oral.
DK2300609T3 (da) Hidtil ukendt flagellinbaserede immunadjuvansforbindelser samt anvendelse deraf
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
BRPI0719210A2 (pt) Uso de compostos espiro-oxindol como agentes terapêuticos
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
BRPI1005670A8 (pt) composições adjuvantes e processos de uso.
BR112012001797A2 (pt) composto bicíclico e uso do mesmo para propósitos médicos
BRPI1007494A2 (pt) composto e uso do mesmo
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
BRPI0717411A2 (pt) Uso de inibidores de iap
BRPI0819821A2 (pt) Preparação e uso de polianilinas para tratamento de água
BRPI0819188A2 (pt) Uso de melanocortinas para tratar sensibilidade à insulina.
BRPI0911332A2 (pt) composições e uso de inibidores de epas1
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]